BamSEC and AlphaSense Join Forces
Learn More

Applied Therapeutics Inc.

NASDAQ: APLT    
Share price (1/9/26): $0.10    
Market cap (1/9/26): $14.5 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 14 pages Unsecured Promissory Note
12/34/56
EX-10.1
from 8-K 42 pages Applied Therapeutics, Inc. Shares of Common Stock (Par Value $0.0001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-10.1
from 10-Q 14 pages We Are Pleased to Offer You Full Time Employment With Applied Therapeutics Inc. (The “Company”) Under the Terms Set Forth in This Offer Letter (The “Offer Letter”), Effective as of Your Start Date With the Company (Such Actual Date of Your Commencement of Employment Shall Be Referred to Herein as the “Start Date”). 1. Employment by the Company. (A) Position. You Will Serve as the Company’s Chief Regulatory Officer (“Cro”) Until Such Time as Your Employment Is Terminated in Accordance With Section 8 Below. During the Term of Your Employment With the Company, You Will Devote Your Best Efforts and Attention to the Business of the Company
12/34/56
EX-10.3
from 8-K 11 pages Confidential
12/34/56
EX-10.2
from 8-K 5 pages Applied Therapeutics Inc. Letter Amendment to Offer Letter
12/34/56
EX-10.1
from 8-K 13 pages We Are Pleased to Offer You Full Time Employment With Applied Therapeutics Inc. (The “Company”) Under the Terms Set Forth in This Offer Letter (The “Offer Letter”), Effective as of Your Start Date With the Company (Such Actual Date of Your Commencement of Employment Shall Be Referred to Herein as the “Start Date”). 1. Employment by the Company
12/34/56
EX-10.5
from 10-Q 32 pages Applied Therapeutics, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: April 24, 2019 Approved by the Stockholders: April 26, 2019 Ipo Date: May 13, 2019
12/34/56
EX-10.5
from 10-Q 32 pages Applied Therapeutics, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: April 24, 2019 Approved by the Stockholders: April 26, 2019 Ipo Date: May 13, 2019
12/34/56
EX-10.2
from 8-K 10 pages Confidential
12/34/56
EX-10.1
from 8-K 13 pages Dale Hooks April 9, 2024 1. Employment by the Company. (A) Position. You Will Serve as the Company’s Chief Commercial Officer (“Cco”) Until Such Time as Your Employment Is Terminated in Accordance With Section 8 Below. During the Term of Your Employment With the Company, You Will Devote Your Best Efforts and Attention to the Business of the Company
12/34/56
EX-10.2
from 8-K 53 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 12 pages Constantine Chinoporos December 28, 2023 1. Employment by the Company
12/34/56
EX-10.1
from 8-K 13 pages Les Funtleyder November 17, 2023 1. Employment by the Company
12/34/56
EX-10.1
from 8-K 22 pages October 12, 2023 Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, Ny 10017 Re: Warrant Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.2
from 8-K 30 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement
12/34/56
EX-10.9
from 10-K 88 pages Exclusive License and Supply Agreement by and Between Applied Therapeutics, Inc. and Mercury Pharma Group Limited January 3, 2023
12/34/56
EX-10.15
from 10-K 3 pages ​ ​ Confidential Steve Ortega 9 Bogert Avenue White Plains, Ny 10606 ​ Dear Steve: ​
12/34/56
EX-10.1
from 8-K 12 pages Charles (Chuck) Silberstein, MD May 20, 2020 1. Employment by the Company
12/34/56